Sinocelltech(SH:688520) Jin Rong Jie·2025-08-19 12:07Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Shenzhou Cell, which has a high PE ratio compared to its industry peers [1][2] - As of August 19, Shenzhou Cell's stock closed at 71.4 yuan, down 2.19%, with a rolling PE ratio of 313.20 and a total market capitalization of 31.797 billion yuan [1] - The average PE ratio for the biopharmaceutical industry is 73.41, with a median of 45.28, placing Shenzhou Cell at the 72nd position among its peers [1][2] Group 2 - As of the first quarter of 2025, 17 institutions hold shares in Shenzhou Cell, with a total of 2.7733 million shares valued at 166 million yuan [1] - The company specializes in the research and commercialization of biopharmaceutical products for various diseases, including cancer and autoimmune diseases, with key products such as SCT800 and SCT400 [1] - In the latest financial report for the first quarter of 2025, Shenzhou Cell reported a revenue of 520 million yuan, a year-on-year decrease of 15.15%, and a net profit of 63.768 million yuan, down 14.06%, with a gross margin of 94.88% [1]